Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Jan-Niklas Eckardt, Marius Bill, Konstanze Döhner, Christian Rausch, Klaus H Metzeler, Karsten Spiekermann, Sebastian Stasik, Tim Sauer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. H. Brummendorf, Utz Krug, Bernhard Wörmann, Hermann Einsele, Wolfgang Hiddemann, Dennis Görlich, Maria Cristina Sauerland, Björn Steffen, Andreas Neubauer, Andreas Burchert, Kerstin Schaefer-Eckart, Wolfgang E. Berdel, Christoph Schliemann, Stefan W. Krause, Mathias Hänel, Maher Hanoun, Martin Kaufmann, Lars Fransecky, Jan Braess, Johannes Schetelig, Jan Moritz Middeke, Lars Bullinger, Michael Heuser, Felicitas R Thol, Hubert Serve, Claudia D Baldus, Uwe Platzbecker, Carsten Mueller-Tidow, Barbora Weinbergerova, Jiri Mayer, Pierre-Yves Dumas, Sarah Bertoli, Eric Delabesse, Christian Récher, Arnaud Pigneux, Tobias Herold, Arnold Ganser, Hartmut Döhner, Martin Bornhäuser, Christian Thiede, Christoph Röllig

Blood (2024) 144 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2024-201945

Published: 2024

Journal Articles

Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Blood (2024) 144 (Supplement 1): 58.

https://doi.org/10.1182/blood-2024-205592

Published: 2024

Journal Articles

Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study

Pierre-Yves Dumas, Sarah Bertoli, Clémence Santana, Mael Heiblig, Thibaut Leguay, Suzanne Tavitian, Eric Delabesse, Émilie Klein, Emmanuelle Tavernier, Martin Carre, Gaspar Aspas Requena, Anne Banos, Norbert Vey, Arnaud Pigneux, Christian Récher, Sylvain Garciaz

Blood (2024) 144 (Supplement 1): 4275.

https://doi.org/10.1182/blood-2024-210596

Published: 2024

Journal Articles

ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction

Abhishek Maiti, Pierre Yves Dumas, Pierre Peterlin, Daniel Morillo, Jose Torregrosa, Paul B. Koller, Maelle Mairesse, Patrick Brune, Emmanuel Valenitn, Aude De Gassart, Katrien Lemmens, Daniel Olive, Naval Daver, Stephan Braun, Sylvain Garciaz

Blood (2024) 144 (Supplement 1): 2876.

https://doi.org/10.1182/blood-2024-193493

Published: 2024

Journal Articles

Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study

Blood (2023) 142 (Supplement 1): 975.

https://doi.org/10.1182/blood-2023-173518

Published: 2023

Journal Articles

Clonal Dynamics of FLT3 -ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin

Romane Joudinaud, Augustin Boudry, Laurène Fenwarth, Sandrine Geffroy, Mikaël Salson, Herve Dombret, Céline Berthon, Arnaud Pigneux, Delphine Lebon, Lamya Haddaoui, Raphael Itzykson, Christian Recher, Audrey Bidet, Eric Delabesse, Mathilde Hunault, Claude Preudhomme, Nicolas Duployez, Pierre-Yves Dumas

Blood (2023) 142 (Supplement 1): 976.

https://doi.org/10.1182/blood-2023-182018

Published: 2023

Journal Articles

Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1 -Mutated Acute Myeloid Leukemia - a Filo Study

Corentin Orvain, Sarah Bertoli, Pierre Peterlin, Yohan Desbrosses, Pierre-Yves Dumas, Alexandre Iat, Marie Anne Hospital, Martin Carre, Emmanuelle Tavernier, Anne Bouvier, Audrey Bidet, Sylvie Tondeur, Florian Renosi, Eric Delabesse, Arnaud Pigneux, Hunault-Berger Mathilde, Christian Recher

Blood (2023) 142 (Supplement 1): 421.

https://doi.org/10.1182/blood-2023-184848

Published: 2023

Journal Articles

Mutational Profile and Dynamics of PPM1D -Mutant Clones in the Spectrum of Myeloid Disorders

Blood (2023) 142 (Supplement 1): 4064.

https://doi.org/10.1182/blood-2023-189428

Published: 2023

Journal Articles

Association between Molecular Profile and Outcome after Intensive Chemotherapy in Patients > 60 Years with Adverse Cytogenetic Risk and/or Secondary Acute Myeloid Leukemia - a Filo Study

Corentin Orvain, Anne Bouvier, Audrey Bidet, Pierre-Yves Dumas, Sarah Bertoli, Odile Blanchet, Sylvain Thepot, Aline Schmidt, Arnaud Pigneux, Eric Delabesse, Christian Recher, Hunault-Berger Mathilde

Blood (2023) 142 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2023-184815

Published: 2023

Journal Articles

FLT3 Ligand Kinetic Profile Predicts Response to Treatment and Event-Free Survival (EFS) in Adults with High-Risk MDS/CMML Receiving CPX-351: A GFM Study

Pierre Peterlin, Joëlle Gaschet, Pascal Turlure, Marie-Pierre Gourin, Pierre-Yves Dumas, Sylvain Thepot, Ana Berceanu, Sophie Park, Marie Anne Hospital, Thomas Cluzeau, Jose-Miguel Torregrosa-Diaz, Louis Drevon, Rosa Sapena, Fatiha Chermat, Sophie Dimicoli-Salazar, Maxime Jullien, Pierre Fenaux, Patrice Chevallier

Blood (2023) 142 (Supplement 1): 6469.

https://doi.org/10.1182/blood-2023-173741

Published: 2023

Journal Articles

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Sylvain Garciaz, Sarah Bertoli, David A Sallman, Justine Decroocq, Pierre-Yves Dumas, Amine Belhabri, Corentin Orvain, Gaspar Aspas Requena, Celestine Simand, Kamel Laribi, Martin Carré, Alberto Santagostino, Ludovic Gabellier, Marie Anne Hospital, Ariane Mineur, Arnaud Pigneux, Norbert Vey, Christian Récher

Blood (2023) 142 (Supplement 1): 161.

https://doi.org/10.1182/blood-2023-185437

Published: 2023

Journal Articles

Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Blood (2023) 142 (Supplement 1): 967.

https://doi.org/10.1182/blood-2023-179376

Published: 2023

Journal Articles

Venetoclax and Azacitidine for Molecular Relapse during First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Study from the Dataml Registry

Jules Higué, Pierre-Yves Dumas, Laetitia Largeaud, Audrey Bidet, Émilie Klein, Olivier Mansier, Lucie Rigolot, Eric Delabesse, Anne Banos, Suzanne Tavitian, Thibaut Leguay, Sarah Guenounou, Edouard Forcade, Sarah Bertoli, Arnaud Pigneux, Christian Recher

Blood (2023) 142 (Supplement 1): 2887.

https://doi.org/10.1182/blood-2023-180773

Published: 2023

Journal Articles

Real-World Treatment Patterns and Clinical Outcomes in Newly Diagnosed Acute Myeloid Leukemia with and without mIDH1 Treated with Intensive Chemotherapy from an International Real-World Database (REAL-IDH)

Joshua F. Zeidner, Priyanka Mehta, Benyam Muluneh, Sarah Bertoli, Pierre-Yves Dumas, Arnaud Pigneux, Cédric Fernandez, Hélène Derrien, Christian Recher

Blood (2023) 142 (Supplement 1): 3816.

https://doi.org/10.1182/blood-2023-188548

Published: 2023

Journal Articles

Tyrosine Kinase Inhibitors with Intensive Chemotherapy in AML with t(9;22)(q34.1;q11.2)/ BCR::ABL1 : Time to Reconsider Prognostic Risk? a Study from the Dataml Registry

Camille Gondran, Pierre-Yves Dumas, Audrey Bidet, Emilie Bérard, Suzanne Tavitian, Thibaut Leguay, Françoise Huguet, Isabelle Luquet, Émilie Klein, Audrey Sarry, Anne-Charlotte De Grande, Eric Delabesse, Édouard Forcade, Cécile Borel, Arnaud Pigneux, Christian Recher, Laetitia Largeaud, Sarah Bertoli

Blood (2023) 142 (Supplement 1): 1473.

https://doi.org/10.1182/blood-2023-180817

Published: 2023

Journal Articles

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2864.

https://doi.org/10.1182/blood-2023-190128

Published: 2023

Journal Articles

Levofloxacin to Prevent Bacterial Infection in Patients with Acute Myeloid Leukemia Treated By Azacitidine and Venetoclax: A Study from the Dataml Registry

Blood (2023) 142 (Supplement 1): 7443.

https://doi.org/10.1182/blood-2023-182117

Published: 2023

Journal Articles

Overlapping features of therapy-related and de novo NPM1 -mutated AML

Blood (2023) 141 (15): 1846–1857.

https://doi.org/10.1182/blood.2022018108

Published: 2023

Includes: Supplemental data

Journal Articles

Gilteritinib Activity in Refractory or Relapsed FLT3 -Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Blood (2022) 140 (Supplement 1): 8996–8998.

https://doi.org/10.1182/blood-2022-159125

Published: 2022

Journal Articles

Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)

Sylvain Garciaz, Justine Decroocq, Sarah Bertoli, Amine Belhabri, Pierre-Yves Dumas, Celestine Simand, Kamel Laribi, Alberto Santagostino, Martin Carre, Aline Schmidt, Gaspard Aspas Requena, Chantal Himberlin, Marie-Anne Hospital, Christian Recher, Norbert Vey

Blood (2022) 140 (Supplement 1): 6147–6148.

https://doi.org/10.1182/blood-2022-158247

Published: 2022

NARROW

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study

ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction

Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study

Clonal Dynamics of FLT3 -ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin

Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1 -Mutated Acute Myeloid Leukemia - a Filo Study

Mutational Profile and Dynamics of PPM1D -Mutant Clones in the Spectrum of Myeloid Disorders

Association between Molecular Profile and Outcome after Intensive Chemotherapy in Patients > 60 Years with Adverse Cytogenetic Risk and/or Secondary Acute Myeloid Leukemia - a Filo Study

FLT3 Ligand Kinetic Profile Predicts Response to Treatment and Event-Free Survival (EFS) in Adults with High-Risk MDS/CMML Receiving CPX-351: A GFM Study

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Venetoclax and Azacitidine for Molecular Relapse during First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Study from the Dataml Registry

Real-World Treatment Patterns and Clinical Outcomes in Newly Diagnosed Acute Myeloid Leukemia with and without mIDH1 Treated with Intensive Chemotherapy from an International Real-World Database (REAL-IDH)

Tyrosine Kinase Inhibitors with Intensive Chemotherapy in AML with t(9;22)(q34.1;q11.2)/ BCR::ABL1 : Time to Reconsider Prognostic Risk? a Study from the Dataml Registry

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Levofloxacin to Prevent Bacterial Infection in Patients with Acute Myeloid Leukemia Treated By Azacitidine and Venetoclax: A Study from the Dataml Registry

Overlapping features of therapy-related and de novo NPM1 -mutated AML

Gilteritinib Activity in Refractory or Relapsed FLT3 -Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only